Weiss Ratings Reiterates Sell (D-) Rating for Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC)

Key Points

• Weiss Ratings has reaffirmed a "sell (D-)" rating for Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC), indicating concerns about the company's stock performance.
• The stock opened at $10.62 and has a recent 12-month high of $10.85 and a low of $9.95.
• Several institutional investors have increased their stakes in Oaktree Acquisition Corp. III, with notable contributions from Clear Street LLC and others acquiring new stakes during the second quarter.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

Oaktree Acquisition Corp. III Life Sciences Price Performance

OACC opened at $10.62 on Friday. Oaktree Acquisition Corp. III Life Sciences has a 12-month low of $9.95 and a 12-month high of $10.85. The firm has a 50 day moving average of $10.50 and a two-hundred day moving average of $10.44.

Institutional Investors Weigh In On Oaktree Acquisition Corp. III Life Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Clear Street LLC grew its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 265.1% during the 2nd quarter. Clear Street LLC now owns 22,000 shares of the company's stock worth $230,000 after purchasing an additional 15,975 shares during the period. Meteora Capital LLC acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 2nd quarter worth approximately $517,000. Kepos Capital LP acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 1st quarter worth approximately $563,000. Picton Mahoney Asset Management acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 1st quarter worth approximately $767,000. Finally, Radcliffe Capital Management L.P. acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 2nd quarter worth approximately $856,000.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.